Biohaven Signs $795M Licensing Deal with SK Biopharmaceuticals for Epilepsy Platform

Key Facts

1Biohaven entered into a licensing agreement with South Korea's SK Biopharmaceuticals for its epilepsy drug platform.

2The deal, which includes the drug Opakalim, is valued at up to $795 million.

In a move reflecting the growing trend of strategic partnerships in the biotech sector to secure research funding, Biohaven has entered into a licensing agreement with South Korea's SK Biopharmaceuticals. The deal grants the South Korean firm rights to Biohaven's epilepsy drug platform, including the candidate Opakalim. The total value of the agreement is structured to reach up to $795 million, significantly bolstering the company's capital through milestone-based payments.

The agreement is designed to allow SK Biopharmaceuticals to lead the development and commercialization of Biohaven's epilepsy treatments. According to reports, this licensing deal serves as a validation of Biohaven's drug platform while providing substantial non-dilutive funding. This collaboration highlights the strategic importance for mid-cap biotech firms to leverage international alliances to advance their clinical pipelines.

Investors will be watching for progress on the clinical and regulatory milestones that trigger the payments within the $795 million deal structure. On the macroeconomic front, the market is awaiting the release of the FOMC minutes later today, August 26, 2026, which may influence broader risk appetite and investment flows into the biotechnology sector.

Sources:

reuters.com